Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BMMNCs for Severe Pediatric TBI
NCT01851083Phase 2Completed
- Sponsor
- UTHealth Houston
- Start
- Aug 2013
- Primary completion
- Sep 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in traumatic brain injury (TBI) comparing autologous bone marrow mononuclear cells with placebo infusion (2 arms). Primary endpoint: Brain white matter and gray matter structural preservation on diffusion tensor magnetic resonance imaging (DTMRI) at 1 year. Started Aug 2013; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT01851083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01851083.